Nizatidine Shortage: What Providers and Prescribers Need to Know in 2026

Nizatidine (formerly marketed as Axid) is an H2 receptor antagonist used for the treatment of active duodenal and gastric ulcers, maintenance therapy for duodenal ulcer healing, GERD, and erosive esophagitis. While nizatidine is not on the FDA's official Drug Shortage Database in 2026, prescribers may encounter patients who report difficulty filling nizatidine prescriptions at their local pharmacy. This guide summarizes the availability landscape and provides actionable clinical guidance.

Current Availability Status (2026)

Nizatidine is not on the FDA Drug Shortage Database as of 2026. Generic nizatidine 150 mg and 300 mg capsules are manufactured by multiple companies including Glenmark, Amneal, Apotex, and Teva. National supply is adequate, but localized stocking issues persist at individual pharmacies — particularly smaller pharmacies in low-density prescribing areas.

The root cause of localized access issues is reduced demand following the 2019–2020 NDMA-related recalls and the subsequent shift of many patients to famotidine or PPIs. Some pharmacies have not rebuilt their nizatidine inventory to pre-2020 levels. The prescription-only status of nizatidine (vs. OTC famotidine and cimetidine) further limits its stocking priority at high-volume retail chains.

NDMA Recalls: Clinical Context for Prescribers

In late 2019, the FDA identified NDMA (N-nitrosodimethylamine), a probable carcinogen, in some lots of ranitidine and nizatidine above the acceptable daily intake limit of 96 nanograms per day. Ranitidine was fully withdrawn from the U.S. market in April 2020. Nizatidine was not fully withdrawn — the FDA found that, unlike ranitidine, nizatidine does not appear to inherently degrade into NDMA — but several manufacturers voluntarily recalled specific lots due to contamination.

Compliant nizatidine from tested manufacturers was cleared and remained on the market through 2021 and beyond. There are no current NDMA-related safety concerns for nizatidine lots from compliant manufacturers in 2026. A recent study from Japan (Iwagami et al., 2021) analyzing data from 2005–2018 did not find an elevated cancer risk associated with nizatidine use compared to other H2 blockers.

Therapeutic Alternatives: Evidence-Based Substitution Guidance

If a patient cannot access nizatidine, the following substitution options are appropriate based on clinical indication:

For GERD and Heartburn:

Famotidine (Pepcid) 20–40 mg: H2 blocker; OTC available at lower doses; fewest drug interactions of the H2 class; consider 20 mg BID for symptom management or 40 mg QHS for GERD. A dose of famotidine 20 mg BID is generally considered equivalent to nizatidine 150 mg BID.

PPIs (first-line for moderate-severe GERD): Omeprazole 20 mg QD, pantoprazole 40 mg QD, or esomeprazole 20–40 mg QD are preferred by ACG guidelines for erosive esophagitis, frequent GERD, or cases unresponsive to H2 blockers.

For Active Peptic Ulcer (Duodenal or Gastric):

Famotidine 40 mg QHS: Comparable to nizatidine 300 mg QHS for active duodenal ulcer treatment; well tolerated

PPI + testing for H. pylori: In patients with active peptic ulcer disease, H. pylori testing and eradication should be prioritized per current ACG guidelines, using PPI-based triple therapy if H. pylori positive.

Formulary and Insurance Considerations

Nizatidine is covered by most commercial and Medicare Part D plans, typically at Tier 1 or Tier 2, given its generic-only status. However, some formularies have moved nizatidine to a lower priority tier since the NDMA recalls, favoring famotidine as the preferred H2 blocker. If prior authorization is required for nizatidine on your patient's plan, requesting a formulary exception to famotidine — which is often Tier 1 or even available OTC — may be faster than an appeal.

Helping Patients Find Nizatidine When They Need It

For patients who specifically need nizatidine and cannot switch, consider directing them to medfinder for providers. medfinder contacts local pharmacies on behalf of patients to identify which ones can fill a specific prescription — including nizatidine — and texts results directly to the patient. This can significantly reduce the burden on both patients and your office staff from fielding calls about where to fill prescriptions.

Key Takeaways for Prescribers

Nizatidine is not in a declared FDA shortage in 2026, but localized pharmacy stock issues are common

The brand Axid is discontinued; only generics from multiple manufacturers remain

The 2020 NDMA recalls are resolved; compliant nizatidine carries no current NDMA warning

Famotidine is the preferred H2 blocker substitute; PPIs appropriate for moderate-severe GERD

Most insurance plans cover generic nizatidine at Tier 1–2; no prior authorization typically required

For patients who need nizatidine and can't find it, medfinder can identify in-stock pharmacies nearby

See also: How to Help Your Patients Find Nizatidine in Stock: A Provider's Guide.